SCPC’s Comment Letter on the Request for Information Regarding Reporting on Pharmacy Benefit and Prescription Drug Costs
Today, the Senior Care Pharmacy Coalition (SCPC) responded to questions on data collection impacting PBMs and prescription drug costs. First, SCPC urges the Biden Administration to define long-term care (LTC) pharmacies distinctly from other pharmacies (e.g., retail, mail order, and specialty). In addition, the coalition strongly recommends the new regulation collect information on rebates, fees, and other direct and indirect renumeration (DIR)—creating more transparency into the exchanges between key entities that drive up prescription drug costs. Namely, collecting data between health insurance plans, their Pharmacy Benefit Managers (PBMs), drug manufacturers, and pharmacies. Collecting and publicizing this information will support a broader investigation into the anti-competitive practices of major companies.
Read the full letter here.
Recent Posts
-
Rosenbloom: Curb PBMs’ power
Despite the purported value of pharmacy benefit managers (PBMs), drug prices remain unaffordable for many Americans (“Prescription drug pricing reform must rein in pharmacy benefit managers,” Web, Oct. 18). As middlemen between the manufacturers, pharmacies and consumers, PBMs are notorious for abusive business practices that impact both patients’ wallets and their access to prescription drugs, while gouging unaffiliated pharmacies.
-
Prescription Drug Middleman Potentially Profiting off Veterans
One of the three dominant U.S. pharmacy benefit managers (PBMs)—the middlemen that handle the vast majority of prescription drug plans in the United States—has instituted a scheme that has left roughly 400,000 active-duty and retired military households scrambling for a new pharmacy provider within the next week. Critics say the maneuver is a naked attempt by Express Scripts, the Cigna-owned PBM, to steer beneficiaries toward its own market-leading mail-order pharmacy.
-
The surprising group that will be hit hard by drug pricing reform
By Rachel CohrsSTAT Obviously, pharmaceutical companies are upset that they’re going to lose money from Medicare under Democrats’ new drug pricing law. But there’s another, less obvious group that’s concerned as well — long-term care pharmacies that serve almost entirely Medicare patients, and dispense the drugs that will likely enter the price negotiation program first. […]
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.